PCF Science

The official Twitter account for scientific news from the Prostate Cancer Foundation. Follow us at @PCFNews @

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 https://t.co/VjKSoslJaV 👉 @NEJM paper https://t.co/03FcVSey5n 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU

[Toni Choueiri, MD @DrChoueiri]

Superb presentation by Georgina Long! INTerpath-001: adding personalized mRNA vaccine intismeran to pembrolizumab reduced recurrence/death risk by 42% in resected stage IIB-IV melanoma (HR 0.58). A major step for cancer vaccines! #ESMO26 @OncoAlert @myESMO #ESMO26

[Toni Choueiri, MD @DrChoueiri]

Encouraging OS results in neuroendocrine prostate cancer at #ESMO26!

#KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone.

• mOS: 10.2 vs 7.1 months (HR 0.33)
• rPFS: 5.1 vs 4.0 months (HR 0.66)
• PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16)

No new safety signals observed.

@myESMO @oncoalert

[Joaquin Mateo @quimmateo]

The #ESMO2026 poster on our academic trial with carboplatin in mCRPC guided by RAD51-IF HRD status is now up in hall 5A. Come by and chat with @pablo_cresta @VHIO work with @Dolmos77 @H12Octubre

[Scott Eggener @uroegg]

UCLA Urology has a long history of impactful basic science discoveries, clinical innovation, practice-changing trials, FDA drug/imaging approvals, and mentorship of future leaders.

We are hiring a Vice-Chair of Research: https://t.co/X1A1bYgbWW

DM if questions/nominations

[Ali Arafa @aliarafaa]

Thank you, @EAntonarakis ! Truly honored and grateful to @PCF_Science and the Milken Family Foundation. Thank you for your mentorship, alongside Justin Hwang and @DrJustinDrake , and to the patients who make this work possible. Excited for what's ahead! @UMNCancer

[Michael Hofman @DrMHofman]

Pushing Terbium-161 PSMA Theranostics to 9.5 GBq - VIOLET Clinical Trial results at the #EANM26 @EANM_NucMed

Terbium-161 emits beta radiation like lutetium-177, plus ultra-short range Auger and conversion electrons that may better target micrometastases. Our first-in-human VIOLET trial established safety up to 7.4 GBq (Lancet Oncology 2025).

So we asked: can we go higher? 12 men with mCRPC, 9.5 GBq, up to 6 cycles:
- Remarkably well tolerated: just 1 grade 3 toxicity (anaemia)
- PSA50 response 75%, PSA90 response 33%
- Median PSA-PFS and rPFS not reached

The answer is yes - and we’re not stopping ... Cohort C, a dose-dense cohort with shorter intervals between early cycles, is now underway.

Huge thanks to @PCF_Science Young Investigators @ButeauJames , @LouiseKostos and @AzadOncology , and to the whole @PeterMacCC @pros_tic team who made this investigator-initiated trial possible.

Grateful to @Isotopia_Global and the for their support

#TOP (Top Rated Oral Presentation)

[Adam B. Weiner, MD @Adam_Weiner535]

🚨 Focal salvage HDR brachy for radiorecurrent #prostatecancer🚨

📜@JCO_ASCO

👥 n=62, intraprostatic radiorecurrence after prior RT, multi-institutional
📊 Phase 1/2, dose-escalated focal salvage HDR, up to 30 Gy in 1 to 2 fractions
⏱️ Median f/u 39.4 mo

✅ No acute grade 3 toxicity; late grade 3 in 2 pts (3.2%)
✅ 3-yr bPFS 62.7%, MFS 85.9%
✅ Higher Decipher GC score tracked w/ worse bPFS, rPFS, MFS; all 4 pts w/ GC >0.85 recurred
⚠️ Small GC subset (n=31), single-arm, hypothesis-generating

🎯 Focal salvage HDR is well tolerated & a genomic classifier may prognosticate

🔗 https://t.co/VlLVEBz40x
@UroOnc @urotoday @UrologyTimes @PCF_Science @Davicioni

[Dana-Farber News @DanaFarberNews]

Congratulations to @DanaFarber's Mary-Ellen Taplin, MD, who was honored with the @PCFNews Women in Science Lifetime Achievement Award. @DanaFarber_GU

Read more: https://t.co/PDWDAliQBo

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Exciting opportunity for Urology & med onc trainees and practicing physicians👉Elevate your clinical and leadership skills at the @PCFnews Leadership Academy! 📍Santa Monica | Dec 3–5, 2026
✅ Expert faculty mentoring ✅ Formal certification
✅ Travel & hotel covered 👉Apply: https://t.co/1caV9Xf22H @urotoday

[Salma Kaochar @Kaochar2]

Not all prostate cancers follow the same molecular playbook! 🧬

🚨🚨Excited to share our new work in @CellReports, spearheaded by graduate student @RizwanKinza 👏and medical student Sai Manikonda👏, revealing distinct genomic alterations and transcriptional programs associated with SPOP-mutant prostate cancer. Another step toward more biologically informed precision oncology! @BCMFromtheLabs

Above all, grateful to the patients who generously contributed their biospecimens to advance cancer research. 💕

A heartfelt thank you to our collaborators for their hard work, support, and invaluable feedback throughout this journey. @CCoarfa @marthamims

And a special shout-out to the often-unsung heroes of science—our reviewers! Their thoughtful and constructive feedback made this a stronger manuscript. 💕

Proud of this team and grateful for the support of @BCMDeptMedicine @bcmhouston, @PCF_Science, CDMRP PCRP and @NIH @theNCI

🔗https://t.co/I4zftcrj5W

[Hsieh Lab @HsiehLab]

This work was funded by @fredhutch, @theNCI, @PCFnews @PCF_Science, @AmericanCancer, @CDMRP, the Larry & Virginia Gordon Endowed Chair, and the Mathews Family, Stinchcomb Family, and Thomas & Patricia Wright memorial funds.

[Hsieh Lab @HsiehLab]

Of note, @yeonsookim_phd (@theNCI K99/R00 awardee) is on the academic job market, so keep an eye out for her. She is an outstanding RNA and cancer biologist!

[Hsieh Lab @HsiehLab]

Ever wonder if tRNAs can regulate the identity of a cancer cell?

@HsiehLab @FredHutch postdoc @yeonsookim_phd did and discovered a single tRNA that can control lineage dependency and drug sensitivity in prostate cancer published today @Nature: https://t.co/V7FHTM0l5M

[CRIS Cancer Foundation @CRISCANCERUK]

What an inspiring few days at the Prostate Cancer Foundation Annual Scientific Retreat! 🔬🌍

We were so proud to present two new CRIS Cancer��PCF Young Investigator Awards to Kirsty Hodgson (Newcastle University) and Nicolás Anselmino (VHIO). 🏆

#ProstateCancer

[Tyler Seibert MD PhD @TylerSbrt]

ARIEL trial: 📄 and🧵on MRI🧲 changes with RT+ADT for #ProstateCancer 👇🏼

@OncoAlert @UroToday @imagingprostate @ASTRO_org @PCF_science @MedwatchHQ #practicalRO #ASTRO26

@adornisch_MD @DrRanaMcKay @medmund14 @UCSDRadMed @DrTylerStewart @UCSDCancer

[Tyler Seibert MD PhD @TylerSbrt]

8️⃣ end

🙏🏼Patients who got in the 🧲 tube for research

🙏🏼Physicians who enrolled patients

🙏🏼Research team for consenting and collecting data

🙏🏼@ASTRO_org @PCF_Science for funding the trial

[Lisa Chesner, PhD @LChesNerd]

Honored to give my first presentation as a PI at a fantastic Keystone Symposium, “Hormonal influences on immunity and cancer across the lifespan” organized by Suzanne Conzen, Amy Moran, and James DeGregori.

[Andrea Miyahira @AndreaMiyahira]

This account is hacked, in case anyone is wondering why “Howard Soule” has suddenly begun spewing out financial “advice.” Unfollow and find the real Dr. Soule on LinkedIn instead.

[Prostate Cancer Foundation @PCFnews]

The world’s leading prostate cancer researchers came to Carlsbad to share their work, and patients and caregivers came with the questions that matter most.

For 33 years, PCF has brought science and lived experience together to move research forward.

#PCFRetreat26